NO20063368L - Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier - Google Patents
Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveierInfo
- Publication number
- NO20063368L NO20063368L NO20063368A NO20063368A NO20063368L NO 20063368 L NO20063368 L NO 20063368L NO 20063368 A NO20063368 A NO 20063368A NO 20063368 A NO20063368 A NO 20063368A NO 20063368 L NO20063368 L NO 20063368L
- Authority
- NO
- Norway
- Prior art keywords
- urinary tract
- lower urinary
- tract disorders
- alpha
- treatment
- Prior art date
Links
- 208000026723 Urinary tract disease Diseases 0.000 title abstract 3
- 208000014001 urinary system disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04001175A EP1557166A1 (de) | 2004-01-21 | 2004-01-21 | Alpha-aminoamidderivate für die Behandlung von Funktionsstörungen der niedrigen Harnwege |
| PCT/EP2005/000514 WO2005070405A1 (en) | 2004-01-21 | 2005-01-20 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063368L true NO20063368L (no) | 2006-10-12 |
Family
ID=34626470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063368A NO20063368L (no) | 2004-01-21 | 2006-07-20 | Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7718815B2 (de) |
| EP (1) | EP1557166A1 (de) |
| JP (1) | JP2007518763A (de) |
| KR (1) | KR101310882B1 (de) |
| CN (1) | CN100584323C (de) |
| AU (1) | AU2005205903B2 (de) |
| BR (1) | BRPI0506970B8 (de) |
| CA (1) | CA2554047A1 (de) |
| IL (1) | IL176968A (de) |
| NO (1) | NO20063368L (de) |
| NZ (1) | NZ548638A (de) |
| PL (1) | PL380825A1 (de) |
| RU (1) | RU2395504C2 (de) |
| WO (1) | WO2005070405A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2363983A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| RS51411B (sr) * | 2004-09-10 | 2011-02-28 | Newron Pharmaceuticals S.P.A. | Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala |
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| WO2007002885A2 (en) * | 2005-06-29 | 2007-01-04 | University Of Virginia Patent Foundation | Compositions and methods for use of a sodium channel blocker |
| IN266803B (de) | 2005-12-22 | 2015-06-03 | Newron Pharm Spa | |
| KR101491541B1 (ko) | 2006-06-19 | 2015-02-09 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 2-［4-(3- 및 2-플루오로벤질옥시)벤질아미노)프로판 아미드의 제조방법 |
| EP2073806B1 (de) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| WO2008046087A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
| TR201802576T4 (tr) | 2007-06-15 | 2018-03-21 | Newron Pharm Spa | Sübsti̇tüe edi̇lmi̇ş 2-[2-(feni̇l)eti̇lami̇no]alkanami̇t türevleri̇ ve bunlarin sodyum ve/veya kalsi̇yum kanal modülatörleri̇ olarak kullanimi |
| EP3257842B1 (de) | 2007-12-11 | 2020-11-18 | Newron Pharmaceuticals S.p.A. | Therapeutische verwendung von 2-[4-(3- oder 2-fluorbenzyloxy)benzylamino]propanamiden mit hohem reinheitsgrad |
| WO2010045197A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals, Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| HRP20150882T1 (hr) | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| PE20170202A1 (es) | 2009-10-14 | 2017-03-24 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
| RU2596488C2 (ru) | 2010-02-26 | 2016-09-10 | Ксенон Фармасьютикалз Инк. | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
| LT2563355T (lt) | 2010-04-27 | 2016-09-26 | Newron Pharmaceuticals S.P.A. | Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas |
| AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| CN1149223C (zh) * | 1995-03-10 | 2004-05-12 | G·D·瑟尔公司 | 杂环羰基氨基酸羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂 |
| GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| EP2201945B1 (de) * | 1997-11-21 | 2013-03-06 | Purdue Neuroscience Company | Verwendung von substituierten 2-Aminoacetamiden zur Behandlung oder Verbesserung von Angstzuständen |
| GB9727523D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| CN1274306C (zh) * | 2001-09-03 | 2006-09-13 | 纽朗制药有限公司 | 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用 |
| AU2004207010A1 (en) | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channel modulators |
| US20070276046A1 (en) | 2003-08-25 | 2007-11-29 | Patricia Salvati | Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents |
-
2004
- 2004-01-21 EP EP04001175A patent/EP1557166A1/de not_active Withdrawn
-
2005
- 2005-01-20 CA CA002554047A patent/CA2554047A1/en not_active Abandoned
- 2005-01-20 PL PL380825A patent/PL380825A1/pl not_active Application Discontinuation
- 2005-01-20 KR KR1020067014655A patent/KR101310882B1/ko not_active Expired - Lifetime
- 2005-01-20 AU AU2005205903A patent/AU2005205903B2/en not_active Expired
- 2005-01-20 CN CN200580002785A patent/CN100584323C/zh not_active Expired - Lifetime
- 2005-01-20 WO PCT/EP2005/000514 patent/WO2005070405A1/en not_active Ceased
- 2005-01-20 RU RU2006126346/04A patent/RU2395504C2/ru active
- 2005-01-20 NZ NZ548638A patent/NZ548638A/en not_active IP Right Cessation
- 2005-01-20 US US10/586,494 patent/US7718815B2/en not_active Expired - Lifetime
- 2005-01-20 JP JP2006550030A patent/JP2007518763A/ja active Pending
- 2005-01-20 BR BRPI0506970A patent/BRPI0506970B8/pt not_active IP Right Cessation
-
2006
- 2006-07-20 IL IL176968A patent/IL176968A/en active IP Right Grant
- 2006-07-20 NO NO20063368A patent/NO20063368L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007518763A (ja) | 2007-07-12 |
| BRPI0506970A (pt) | 2007-07-03 |
| KR101310882B1 (ko) | 2013-09-25 |
| US7718815B2 (en) | 2010-05-18 |
| EP1557166A1 (de) | 2005-07-27 |
| CN1956714A (zh) | 2007-05-02 |
| IL176968A (en) | 2012-10-31 |
| US20080132567A1 (en) | 2008-06-05 |
| CN100584323C (zh) | 2010-01-27 |
| IL176968A0 (en) | 2006-12-10 |
| NZ548638A (en) | 2010-02-26 |
| HK1103282A1 (zh) | 2007-12-14 |
| AU2005205903A1 (en) | 2005-08-04 |
| BRPI0506970B8 (pt) | 2021-05-25 |
| RU2395504C2 (ru) | 2010-07-27 |
| KR20070007776A (ko) | 2007-01-16 |
| PL380825A1 (pl) | 2007-03-19 |
| WO2005070405A1 (en) | 2005-08-04 |
| AU2005205903B2 (en) | 2010-04-29 |
| CA2554047A1 (en) | 2005-08-04 |
| BRPI0506970B1 (pt) | 2019-08-13 |
| RU2006126346A (ru) | 2008-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20070049L (no) | Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
| EP2286839A3 (de) | Behandlung von Fettleibigkeit und von verwandten Krankheiten | |
| NO20081842L (no) | Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer | |
| MY148985A (en) | 2-aminopyridine analogs as glucokinase activators | |
| NO20092637L (no) | Fremgangsmater for behandling | |
| NO20072665L (no) | Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser | |
| MX2010005345A (es) | Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad. | |
| NO20064732L (no) | Alfa-aminoamidderivater nyttige i behandlingen av urolige bein-syndromet og additive lidelser | |
| BRPI0506970B8 (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior | |
| WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
| PL1919466T3 (pl) | Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| WO2006086693A3 (en) | Medical devices | |
| EA200901062A1 (ru) | Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| NO20073610L (no) | Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase | |
| MX2007010484A (es) | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. | |
| EA200801940A1 (ru) | Применение стробилуринов для лечения нарушений метаболизма железа | |
| WO2007055743A3 (en) | Treatment of obesity and related disorders | |
| WO2006135694A3 (en) | Uii-modulating compounds and their use | |
| WO2008022807A3 (en) | Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis | |
| WO2006109170A3 (en) | Combination therapy for treatment of cardiovascular diseases and related conditions | |
| WO2006042277A3 (en) | Extended release compositions of proton pump inhibitors | |
| WO2007128088A3 (en) | Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases | |
| WO2008057543A3 (en) | Uii-modulating compounds and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |